FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling.

Daiki Kanaoka Mitsuo Yamada Hironori Yokoyama Satoko Nishino Naoshi Kunimura Hiroshi Satoyoshi Shota Wakabayashi Kazunori Urabe Takafumi Ishii Masato Nakanishi

Published in: Cancer research communications (2024)

We found potential vulnerability to CK1α degradation in certain lymphoma cells refractory to IKZF1/3 degraders. Targeting CK1α with FPFT-2216 could inhibit the growth of these cells by activating p53 signaling. Our study demonstrates the potential therapeutic application of CK1α degraders, such as FPFT-2216, for treating lymphoma.

Keyphrases

induced apoptosis
protein kinase
diffuse large b cell lymphoma
signaling pathway
cell cycle arrest
acute lymphoblastic leukemia
oxidative stress
cell death
cancer therapy
human health